Regenxbio Inc (NASDAQ:RGNX)
| 30.24 Delayed Data As of 3:59pm ET |  -0.81 / -2.61%Today’s Change | 27.02 Today|||52-Week Range 50.26 | -33.33% Year-to-Date |
Latest RGNX News | Press Releases
| 4 Reasons Why You Should Add Sarepta (SRPT) to Your Portfolio Nov 26 / Zacks.com - Paid Partner Content | REGENXBIO (RGNX) DMD Gene Therapy Gets Orphan Drug Status Nov 23 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 31.05 |
| Today’s open | 31.23 |
| Day’s range | 30.06 - 31.42 |
| Volume | 13,528 |
| Average volume (3 months) | 436,535 |
| Market cap | $1.3B |
Data as of 3:59pm ET, 11/29/2021
Growth & Valuation
| Earnings growth (last year) | -15.57% |
| Earnings growth (this year) | +230.60% |
| Earnings growth (next 5 years) | +11.81% |
| Revenue growth (last year) | +338.70% |
| P/E ratio | NM |
| Price/Sales | 10.94 |
| Price/Book | 3.07 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| QUREUniqure NV | -0.31 | -1.07% |
| MORMorphoSys AG | +0.11 | +1.11% |
| REPLReplimune Group Inc | -0.40 | -1.38% |
| OCGNOcugen Inc | +0.03 | +0.46% |
Data as of 4:52pm ET, 11/29/2021
Financials
| Next reporting date | March 2, 2022 |
| EPS forecast (this quarter) | $6.79 |
| Annual revenue (last year) | $154.6M |
| Annual profit (last year) | -$111.3M |
| Net profit margin | -71.98% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters Rockville, Maryland |
Forecasts
